Tag Archives: mesothelioma treatments

Making Mesothelioma Cells More Susceptible to Chemotherapy

A potential new mesothelioma drug may have moved a step closer to gaining mainstream acceptance for use in sick patients. Doctors studying the drug say they have found a way to make cells more susceptible to its damaging effects. GDC-0980, also known as Apitolisib, is a class I inhibitor of two cell signaling pathways – P13 and mTOR – both of which play critical roles in regulating the life cycle of cells, including mesothelioma cells. Because mesothelioma is so difficult to treat with standard chemotherapy drugs, researchers around the world are exploring ways to improve treatment by manipulating the vital signaling pathways inside mesothelioma cells. Now, doctors at cancer research centers in the US, the UK, and Switzerland say they … Continue reading Making Mesothelioma Cells More Susceptible to Chemotherapy »

Could a Virus-Delivered Gene Slow Mesothelioma Growth?

Researchers in Japan are enrolling mesothelioma patients into a trial to test whether blocking a growth signaling pathway inside mesothelioma cells could slow down this aggressive cancer or even stop its progression. The hepatocyte growth factor (HGF)/c-Met signal pathway is highly active in mesothelioma and many other types of cancer cells, telling them to grow and replicate quickly. In the lab, scientists have shown that the NK4 gene, which shares a molecular structure similar to HGF, can interrupt this signaling pathway and keep cancer cells from growing out of control. In a new study launched this summer by researchers at several Japanese universities, scientists will be testing a method of delivering NK4 to the site of mesothelioma tumors by administering a virus designed … Continue reading Could a Virus-Delivered Gene Slow Mesothelioma Growth? »

Kidney Cancer Drug Slows Mesothelioma Growth in Mice

A drug that has been shown to slow the growth of renal cell carcinoma may have moved a step closer to becoming a viable addition to the arsenal of patients fighting malignant mesothelioma. Temsirolimus is a kinase inhibitor that appears to work against mesothelioma, in part, by blocking the action of a protein that tells cancer cells to replicate. In laboratory tests on isolated tumor cells, temsirolimus effectively blocked the gene pathway known as mammalian target of rapamycin (mTOR) that is responsible for signaling the growth and division of all types of mesothelioma. Now, a new study conducted by scientists in Greece and the UK suggests that the compound may do the same thing in living patients. The doctors induced … Continue reading Kidney Cancer Drug Slows Mesothelioma Growth in Mice »

European Group Issues Updated Treatment Guidelines for Mesothelioma

physician and colleagues

A group of medical researchers has just released an updated set of clinical practice guidelines for treating patients with malignant pleural mesothelioma, one of the rarest and most treatment-resistant forms of cancer. The guidelines, released by the European Society for Medical Oncology and published in the newest issue of the Annals of Oncology, contain six sets of recommendations designed to support clinicians in the management of mesothelioma from diagnosis to treatment and follow-up. Recommendation for Mesothelioma Diagnosis The updated ESMO mesothelioma guidelines recommend that all patients undergo a thorough occupational history with emphasis on asbestos exposure and a CT scan of their chest. They also recommend that all patients with pleural thickening have a biopsy but do not recommend routine … Continue reading European Group Issues Updated Treatment Guidelines for Mesothelioma »

Extended Survival of Peritoneal Mesothelioma with Repeat Treatment

There is some good news on the research front for patients with recurrent peritoneal mesothelioma. Doctors at the University of New South Wales in Australia say that treating these patients again with surgery and heated chemotherapy is extending lives, sometimes for several years. Peritoneal mesothelioma, which accounts for about 20 percent of mesothelioma cases, occurs on the peritoneal membrane that surrounds abdominal organs. Cytoreductive surgery (CRS) aims to remove as much of that diseased tissue as possible. It is often followed by heated intraperitoneal chemotherapy (HIPEC) to kill any remaining mesothelioma cells and to keep new tumors from starting. The CRS/HIPEC combination has become the gold standard first line treatment for peritoneal mesothelioma. But the authors of a new study … Continue reading Extended Survival of Peritoneal Mesothelioma with Repeat Treatment »

Characteristics of Mesothelioma in Younger Patients

A new report finds that mesothelioma has different characteristics in younger people than it does in the more typical older patients. Mesothelioma is an aggressive and hard-to-treat cancer usually caused by exposure to asbestos. It can take decades to develop and, as a result, is usually thought of as a disease of older people. The vast majority of patients are over 70. However, as a new report in Oncotarget points out, there is a subset of mesothelioma patients under 40 years old. In these patients, mesothelioma can act very differently – and require a different treatment approach – than it does in the older population. The new study relied on data from Surveillance, Epidemiology and End Results (SEER), a national … Continue reading Characteristics of Mesothelioma in Younger Patients »

Treating Mesothelioma with Curcumin: Success May Be Predictable

Clinicians may be a step closer to being able to use curcumin to combat aggressive malignant pleural mesothelioma. Curcumin is the plant polyphenol that gives turmeric its yellow hue and spicy flavor. It has anti-inflammatory properties and has been shown to inhibit the growth of mesothelioma cells from animal models in the laboratory. Now, for the first time, researchers in Australia say they have successfully done the same thing with human cells taken from their own mesothelioma patients. Researcher Sonja Klebe, an Associate Professor at Flinders Medical Centre in South Australia where the new research was conducted, says the breakthrough will allow doctors to predict whether or not a certain mesothelioma patient will benefit from treatment with curcumin. The research … Continue reading Treating Mesothelioma with Curcumin: Success May Be Predictable »

Predicting Long-Term Mesothelioma Survival After Surgery

Most mesothelioma  patients and their families have heard the poor survival statistics associated with this aggressive cancer. But two new studies on two different types of mesothelioma suggest that long term survival is possible with surgery and can even be predictable. The first study was a multi-center analysis conducted in Italy between 2000 and 2010. Researchers retrospectively reviewed the cases of 468 malignant pleural mesothelioma patients who underwent extrapleural pneumonectomy – a radical surgery that involves removing the diseased pleural lining as well as the closest lung. Since most pleural mesothelioma patients die within a year of diagnosis, the research team classified those who lived three years or longer as “long term survivors.” A total of 107 mesothelioma patients (22.9%) fell into … Continue reading Predicting Long-Term Mesothelioma Survival After Surgery »

Lower-Cost Mesothelioma Drug May Be as Effective as Gold Standard

A new study suggests that the lower cost chemotherapy drug Gemzar (gemcitabine) combined with a platinum based agent (cisplatin or carboplatin) may be just as effective at treating advanced pleural mesothelioma as the gold standard mesothelioma drug Alimta (pemetrexed) . Doctors in Turkey, a country with one of the world’s highest rates of mesothelioma, tracked 116 mesothelioma patients who were treated with a combination of Alimta and a platinum drug between 1999 and 2012. During the same period, 30 mesothelioma patients received the alternative combination of Gemzar and a platinum drug. There were no differences between the two groups in terms of age, gender, asbestos exposure, histological subtype, cancer stage or other characteristics.  The mean age of the patients was … Continue reading Lower-Cost Mesothelioma Drug May Be as Effective as Gold Standard »

British Group Highlights Top Ten Mesothelioma Research Priorities

The potential value of immunotherapy, individualized chemotherapy, second-line treatments, and strategies for patient monitoring are among the top ten priorities for mesothelioma research according to British patients, caregivers, and clinicians. The James Lind Alliance specializes in setting priorities for health policy. The group was asked to work with the British National Institute for Health Research to study mesothelioma in the wake of sweeping mesothelioma compensation legislation in 2013. The Priority Setting Partnership brought together mesothelioma patients, caregivers, clinicians and support organizations to develop a research priority list, which was published in the latest issue of Lung Cancer. In all, 453 of the initial mesothelioma surveys were returned and refined into 52 unanswered research questions. Another 202 responders helped reduce that … Continue reading British Group Highlights Top Ten Mesothelioma Research Priorities »